Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease

Press/Media

Period2 Jul 2024

Media coverage

1

Media coverage

  • TitleLilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease
    Media name/outletEagle Times (Claremont, New Hampshire)
    Country/TerritoryUnited States
    Date2/07/24
    PersonsHoward Fillit
View all 1
View less